Form 4: Acadia Pharmaceuticals EVP Mark Schneyer Reports Stock Transactions
SEC Form 4 Filing
Mark Schneyer, EVP and CFO of Acadia Pharmaceuticals, reports the acquisition and disposition of common stock and restricted stock units.
Summary
- Mark C. Schneyer, EVP and CFO of Acadia Pharmaceuticals, filed a Form 4 detailing changes in beneficial ownership.
- On May 1, 2025, Schneyer acquired 6,815 shares of common stock through the vesting of restricted stock units.
- Also on May 1, 2025, 6,815 restricted stock units vested.
- On May 2, 2025, Schneyer disposed of 3,498 shares of common stock at a price of $14.6 per share.
- These sales were mandatory to cover withholding taxes related to the vesting of restricted stock units.
- Following these transactions, Schneyer beneficially owns 62,773 shares of common stock and 13,630 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting stock transactions, which carries a neutral sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company executive, which is common in the pharmaceutical industry.
Key Dates
| Date | Description |
|---|---|
| 05/01/2024 | The restricted stock units vest in four equal annual installments beginning May 1, 2024. |
| 05/01/2025 | Restricted stock units vested, resulting in the acquisition of common stock. |
| 05/02/2025 | Shares of common stock were sold to cover withholding taxes. |
Keywords
Form 4, Beneficial Ownership, Stock Transactions, Acadia Pharmaceuticals, Schneyer, Restricted Stock Units, Common Stock, Vesting, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.